Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer

Cancer Science
Wataru ObaraTomoaki Fujioka

Abstract

Cell division associated 1 (CDCA1) was screened as an oncogene that is overexpressed on several cancers, including prostate cancer. A highly immunogenic HLA-A*2402-restricted epitope peptide corresponding to part of the CDCA1 protein was also identified. A phase I clinical trial was conducted for patients with castration resistant prostate cancer (CRPC) using a CDCA1 peptide vaccination. Twelve patients having HLA-A*2402 with CRPC after failure of docetaxel chemotherapy were enrolled. They received subcutaneous administration of the CDCA1 peptide as an emulsion with Montanide ISA51VG once a week in a dose-escalation manner (doses of 1.0 or 3.0 mg/body, six patients received each dose). The primary endpoint was safety, and the secondary endpoints were the immunological and clinical responses. Vaccination with CDCA1 peptide was well tolerated without any serious adverse events. Peptide-specific cytotoxic T lymphocyte (CTL) responses using ELISPOT assay and dextramer assay were observed in three patients receiving the 1.0 mg dose and five patients receiving the 3.0 mg dose. The median overall survival time was 11.0 months and specific CTL reacting to CDCA1 peptide were recognized in long-surviving patients. CDCA1-derived peptide v...Continue Reading

References

Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
Jan 20, 2005·The Journal of Experimental Medicine·Catherine GermeauPierre G Coulie
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Jolanda M de VriesGosse J Adema
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Sep 5, 2008·International Journal of Cancer. Journal International Du Cancer·Michiko HaraoYasuharu Nishimura
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Nov 11, 2010·Current Cancer Drug Targets·Sara CeccoRiccardo Dolcetti
May 27, 2011·The New England Journal of Medicine·Johann S de BonoUNKNOWN COU-AA-301 Investigators
Aug 2, 2011·Nature Reviews. Drug Discovery·W Joost LesterhuisCornelis J A Punt
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Jul 19, 2013·The New England Journal of Medicine·C ParkerUNKNOWN ALSYMPCA Investigators
Apr 16, 2014·International Journal of Cancer. Journal International Du Cancer·Yusuke TomitaYasuharu Nishimura
Nov 14, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoshihiro YoshitakeMasanori Shinohara
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz

❮ Previous
Next ❯

Citations

Dec 14, 2018·Oncoimmunology·Lucillia BezuLorenzo Galluzzi
Mar 24, 2021·Cell Proliferation·Wensi LiuJianping Li
Jul 3, 2021·Vaccines·Brigida Anna MaioranoEvaristo Maiello

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
biopsy

Clinical Trials Mentioned

NCT01225471

Software Mentioned

JMP

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.